Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Os...(n and less risk of hypercalcemia. In add...),Health

Date:8/5/2009

n and less risk of hypercalcemia. In addition, BA058 in a prefilled cartridge presentation for self-injection has demonstrated long-term stability at room temperature without loss of functionality or impairment of safety and tolerability, an important convenience advantage for patients that would eliminate the refrigeration requirement of daily-injected Forteo(R). Sales of PTH analogs are projected to surpass bisphosphonate sales and reach $2.3 billion by 2018, driven by robust efficacy data in reducing fractures.

About Osteoporosis

Osteoporosis is a leading cause of morbidity and mortality in elderly people worldwide. In the U.S. alone, more than 44 million men and women have osteoporosis or low bone-mineral density. A 50-year-old woman in the U.S. has a 40 percent lifetime risk of osteoporotic fracture. Twenty percent of hip-fracture patients enter long-term care, and half of this group never returns to living independently.

About Radius (www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $106.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

    Contact: Nick Harvey
    Chief Financial Officer
    (617) 551-4704

'/>"/>

SOURCE Radius Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
2. Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
3. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
4. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
10. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis